Our Services
Medical Information
Helpful Resources
Published on: 3/18/2026
When standard antidepressants fail, newer treatments may help. Esketamine, ketamine, and postpartum-specific medications like brexanolone and zuranolone work differently—targeting glutamate to boost neuroplasticity—and can relieve symptoms within hours to days, though responses vary.
Key factors to weigh include eligibility, benefits and risks, in-clinic monitoring requirements, costs and insurance coverage, maintenance plans, and how therapy and lifestyle changes fit in. Full details below can help guide your next steps and clarify when to seek urgent care.
Not sure if these advanced options are right for you? Understanding your symptoms is the essential first step before exploring treatment paths. Take a free, instant, online symptom check to clarify what you're experiencing, identify possible causes, and get personalized guidance on what to do next—so you can have a more informed conversation with your doctor about whether newer therapies could work for you.
Reviewed for medical accuracy: 07/09/2026
If you've taken antidepressants and still feel depressed, you are not alone.
Major depressive disorder (MDD) is one of the most common medical conditions worldwide. While traditional antidepressants help many people, up to one-third of patients do not experience full relief after trying at least one medication. This is often called treatment-resistant depression.
The good news? Mental health science has advanced significantly in recent years. A new generation of novel antidepressants is changing how we understand — and treat — depression.
Let's walk through what that means for you.
Most older antidepressants — such as SSRIs (like sertraline or fluoxetine) and SNRIs (like venlafaxine) — work by increasing levels of brain chemicals such as serotonin and norepinephrine.
They can be highly effective. But they have limitations:
Depression is not caused by just one chemical imbalance. It involves complex interactions between:
That's where novel antidepressants come in.
Novel antidepressants are newer treatments that target different biological pathways than traditional medications. Instead of focusing only on serotonin, they act on other brain systems involved in mood regulation.
The most researched and clinically used novel antidepressants include:
These medications represent a shift in how we treat depression — from slowly adjusting serotonin to rapidly restoring brain communication.
Esketamine and ketamine act on the NMDA receptor, which is part of the glutamate system — the brain's main excitatory network.
Research shows that depression may involve disrupted communication between brain cells. Glutamate-based treatments appear to:
Some patients experience improvement within hours to days, rather than weeks.
Chronic stress and depression can shrink or weaken certain brain regions, including the hippocampus and prefrontal cortex.
Novel antidepressants may:
This represents a biological "reset" rather than a slow chemical adjustment.
One of the most important developments is the rapid reduction of suicidal thoughts in some patients treated with esketamine.
This does not mean it replaces emergency care. But in controlled clinical settings, it has shown meaningful benefit for individuals in severe depressive episodes.
If you are experiencing thoughts of self-harm, that is urgent and requires immediate medical attention.
You may want to speak with a doctor about novel antidepressants if:
These treatments are typically used under psychiatric supervision and may require monitoring in a certified clinic.
Clinical trials published in peer-reviewed journals show that:
However:
They are not miracle cures — but they are real, evidence-based advances.
All medications carry risks. That includes novel antidepressants.
Common considerations include:
Because of potential side effects, esketamine is administered in a healthcare setting under supervision.
Your doctor will assess:
Safety always comes first.
Even the most advanced novel antidepressants work best as part of a broader treatment plan.
Comprehensive care may include:
Medication can open the door. Therapy and lifestyle help keep it open.
If you're unsure whether what you're experiencing qualifies as ongoing depression or need help identifying which symptoms should be discussed with your doctor, you can use this free AI-powered Depression symptom checker to gain personalized insights about your condition and prepare more informed questions for your healthcare provider.
Self-assessment tools are not diagnostic — but they can clarify patterns and next steps.
If you're still depressed after treatment, consider asking:
Bring a list of previous medications you've tried, including dose and duration. That information helps guide next steps.
It's important to be realistic.
But they represent the most significant advancement in depression treatment in decades.
For people who have felt stuck, hopeless, or exhausted by repeated medication failures, they offer something powerful: another scientifically supported option.
If you experience:
You should seek urgent medical care or contact emergency services immediately.
Depression is a medical condition — not a personal weakness — and severe symptoms deserve immediate attention.
If you're still depressed after treatment, it does not mean:
It may simply mean your brain requires a different biological approach.
Novel antidepressants are reshaping modern psychiatry by targeting new brain pathways, promoting neuroplasticity, and offering faster relief for some patients — especially those with treatment-resistant depression.
The next step is not to lose hope. It's to have a well-informed conversation with a qualified healthcare professional.
If your symptoms are persistent, worsening, or feel life-threatening in any way, speak to a doctor immediately.
Depression is serious — but it is also treatable. And science continues to move forward.
(References)
* McIntyre RS, Lépine JP, Gendarme V, Mansur RB, Lee Y. Novel Treatments for Treatment-Resistant Depression. J Clin Psychiatry. 2021 Apr 13;82(3):E1-E1. doi: 10.4088/JCP.21NR03781. PMID: 33857321.
* Micale V, Mazzon E, De Salve A, Grasso M. Emerging rapid-acting antidepressants: novel mechanisms and clinical implications. Front Neurosci. 2023 Feb 27;17:1140924. doi: 10.3389/fnins.2023.1140924. PMID: 36923485; PMCID: PMC10005740.
* Sawiak A, Włodarczyk A, Wasilewski D, Mierzejewski P. Ketamine and Esketamine in the Treatment of Depression: A Literature Review. J Clin Med. 2023 Nov 28;12(23):7404. doi: 10.3390/jcm12237404. PMID: 38068595; PMCID: PMC10707767.
* Sanacora G, Abdallah CG, Krystal JH. Psychedelics in the treatment of mood disorders: The next generation of antidepressants? Nat Rev Drug Discov. 2022 Dec;21(12):883-884. doi: 10.1038/d41573-022-00179-8. PMID: 36284145.
* Kularathna S, Siskind D, Hides L, Holgate G, Parker G. Novel therapeutic strategies for treating depression: An update. Aust N Z J Psychiatry. 2023 Oct;57(10):1136-1153. doi: 10.1177/00048674231189785. Epub 2023 Jul 26. PMID: 37492167.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.